Analysts Set BioAge Labs, Inc. (NASDAQ:BIOA) PT at $45.00

BioAge Labs, Inc. (NASDAQ:BIOA) has earned a consensus recommendation of “Moderate Buy” from the four research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $45.00.

A number of research analysts recently weighed in on the stock. Citigroup lifted their target price on shares of BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Piper Sandler initiated coverage on BioAge Labs in a report on Tuesday, January 27th. They set an “overweight” rating on the stock. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Oppenheimer assumed coverage on BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 target price for the company. Finally, Morgan Stanley set a $23.00 price target on BioAge Labs in a report on Wednesday, February 4th.

Insider Activity

In other news, CEO Kristen Fortney sold 233,107 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total value of $4,223,898.84. Following the transaction, the chief executive officer owned 976,949 shares of the company’s stock, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul D. Rubin sold 7,433 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total transaction of $139,368.75. The SEC filing for this sale provides additional information. Insiders have sold a total of 267,540 shares of company stock worth $4,895,168 over the last quarter. Insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in BioAge Labs by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after acquiring an additional 93,694 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of BioAge Labs during the 4th quarter valued at approximately $13,892,000. Geode Capital Management LLC grew its holdings in shares of BioAge Labs by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock valued at $7,826,000 after purchasing an additional 28,646 shares in the last quarter. State Street Corp increased its position in BioAge Labs by 113.4% in the fourth quarter. State Street Corp now owns 422,846 shares of the company’s stock worth $5,594,000 after purchasing an additional 224,735 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in BioAge Labs in the fourth quarter worth $5,406,000.

BioAge Labs Price Performance

Shares of NASDAQ:BIOA opened at $21.22 on Friday. BioAge Labs has a 1-year low of $2.88 and a 1-year high of $24.00. The company has a market capitalization of $760.74 million, a P/E ratio of -13.96 and a beta of 1.22. The firm’s 50 day simple moving average is $19.94 and its two-hundred day simple moving average is $12.34.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.